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A variety of backbone-modified peptides were desorbed by fast atom bombardment and colli- 
sionally activated. These peptide modifications involve the replacement ofa normal [CONH] 
peptide linkage with such groups as thiomethylene ether (CH2S), thioamide (CSNH), 
methyleneamine (CH2NH), and thiomethylene sulfoxide (CH2SO) moieties. Modified lin- 
ear peptides decompose to give fragmentations characteristic of the modifications as well as 
typical peptide bond fragments. The presence of a replacement group in cyclic peptides can 
induce new fragmentations. The presence of other functional groups, such as an exocyclic 
N-terminal residue, however, can dominate the observed fragmentations. Upon collisional 
activation, unmodified linear peptides fragment to give N-terminal ions as the most abundant 
daughter ions. In comparison, ~[CH2NH] and ~[CH2S ] modified linear peptides decompose 
to give prominent C-terminal sequence ions. The ~[CH2SO] modified linear peptides, how- 
ever, fragment into both N- and C-terminal ions of high relative abundance. Depending on 
the modification, daughter ions or internal fragment ions are observed that are characteristic 
of the amide bond replacement. Useful structural information can therefore be obtained. (J 
Am Soc Mass Spectrom 1990, 1, 174-182) 
I 
t has been shown recently by Spatola et al. [1-7] 
that variations in the backbone elements in pep- 
tides are useful for determining the functional role 
of the normal [CONH] peptide linkage. These varia- 
tions include the replacement of [CONH] bonds in lin- 
ear and cyclic peptides with such groups as thiomethy- 
lene ether (CHaS), thiomethylene sulfoxide (CH2SO), 
thioamide (CSNH), and methyleneamine (CH2NH) 
moieties. The effects of such modifications include (1) 
enhanced receptor selectivity, (2) increased resistance 
to enzymatic degradation, and (3) altered solubility 
properties. 
In one example, modified cyclic peptides contain- 
ing a ~[CH2S] amide bond replacement show a higher 
potency for 3 receptors than the corresponding cyclic 
parent peptide [2]. It was proposed that because the 
rotational energy barrier for a CH2S bond is lower than 
that of an amide bond, the cyclic pseudopeptides con- 
tain more flexible ring structures. Therefore, this en- 
hanced flexibility may be the reason for the relatively 
high potency toward both /~ and ~ receptor classes. 
In comparison, linear pseudopeptides containing the 
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thiomethylene substitution show a decrease in both 
potency and receptor selectivity [3]. 
In addition, the position of the amide bond replace- 
ment has an effect on the receptor affinity. For exam- 
ple, in comparing the receptor selectivity of a peptide 
modified with a thioamide linkage at the second pep- 
tide bond versus that of one modified at the fourth 
peptide bond, the former selectively strengthens bind- 
ing to the ~ receptor whereas the latter shows very little 
difference in selectivity from that of the parent peptide 
[4]. This suggests, therefore, that the C-terminal por- 
tion of the peptide has little influence on the relative 
receptor affinity of the peptide [4]. 
Benovitz and Spatola [8] also studied the effect of 
amide bond replacements with respect o resistance 
toward enzymatic degradations. The presence of a 
thiomethylene ether eplacement apparently offers en- 
zymatic degradation protection to amide bonds several 
residues removed from the originally labile linkages. 
Where manipulation of side-chain elements in pep- 
tides has traditionally been used to achieve such prop- 
erties as decreased enzyme resistance or enhanced bio- 
logical activities, modifications in the backbone chains 
of peptides may provide an alternative mechanism for 
obtaining similar biological responses. 
The development of mass spectrometry for the 
© 1990 American Society for Mass Spectrometry Received September 12, 1989 
1044=0305/90/$3.50 Accepted December 13, 1989 
J Am Soc Mass Spectrom 1990, 1, 174-182 MS/MS OF BACKBONE-MODIFIED PEPTIDES 175 
structure determination a d amino acid sequencing of 
peptides has been an active area of research for many 
years and has been recently reviewed [9, 10]. A vari- 
ety of ionization techniques have been utilized in an ef- 
fort to characterize these bi0molecules. Early studies of 
peptides involved electron ionization (EI) and chemical 
ionization (CI) mass spectrometry asa means of anal- 
ysis. However, chemical derivatizations (i.e., perme- 
thylation and reduction to polyamino alcohols) were 
often necessary to make these polar molecules more 
amenable to EI and CI. Another disadvantage is that 
both methods are limited to small (i.e., deca-) pep- 
tides. To overcome these disadvantages, researchers 
turned to other desorption techniques. Field desorp- 
tion (FD) and plasma desorption (PD) have demon- 
strated the capability of ionizing polar biomolecules 
such as peptides [11-15]. These techniques are advan- 
tageous because no derivatizations are necessary and 
very large peptides can be analyzed. However, PD re- 
quires special instrumentation, and FD is not a routine 
technique. 
Since its inception, fast atom bombardment mass 
spectrometry (FAB/MS) [16] has become a widely used 
desorption technique for the analysis of peptides [9, 
10]. In addition, the FAB/MS analysis of backbone- 
modified peptides [17] has become very useful, be- 
cause these pseudopeptides cannot be identified in 
an Edman degradation. However, there are several 
disadvantages a sociated with FAB/MS for the struc- 
tural elucidation of biomolecules. First, mass spec- 
tra can be complicated by the high level of chemical 
background noise and, second, often few structurally 
informative fragment ions are produced. Therefore, 
FAB in conjunction with tandem mass spectrometry 
(FAB/MS/MS) has been developed to alleviate some of 
these problems associated with FAB/MS. 
In coupling FAB with MS/MS, the ion of inter- 
est is focused through the first-stage spectrometer 
(MS-I) into a collision cell and is collisionally acti- 
vated to fo~m its daughter ions. The fragment ions are 
subsequently analyzed by scanning the second-stage 
spectrometer (MS-II). The resulting collision-activated 
decomposition (CAD) spectra often reveal structural 
information. Since the early reports on the applica- 
tion of the combined techniques of FAB and MS/MS 
for the determination f peptides [18-20], FAB/MS/MS 
has become widely used for the analysis of linear pep- 
tides (see refs 21-29 for representative papers), and 
the area has recently been reviewed [9, 28, 29]. It has 
been useful not only for the sequence determination 
of linear peptides, but also for the determination of
cyclic peptides [9, 28-34], which are very difficult o se- 
quence by traditional mass spectrometric techniques. 
Fast atom bombardment coupled with MS/MS offers 
several advantages for the analysis of peptides: 
1. The need for the complete separation of peptide 
mixtures is eliminated. 
2. The technique is applicable to N-blocked peptides 
as well as those containing modified amino acids. 
3. Information is obtained from both N- and C- 
terminal sequences. 
4. Matrix ions are eliminated. 
5. Parent ion-daughter ion relationships in mixtures 
can be determined. 
As part of our continuing interest in the applica- 
tion of FAB/MS/MS for the structural determination f 
biomolecules [35-38], we investigated the CAD spec- 
tra of several backbone-modified peptides. These com- 
pounds cannot be sequenced by normal biochemical 
techniques such as Edman degradation. Thus, it would 
be extremely useful if these types of modifications 
could be determined by FAB/MS/MS. We now report 
the results of our study. 
Experimental 
Chemi~Is 
The peptides used in this study are listed in Table 1. 
The "psi bracket" is representative of the nomencla- 
ture of amide bond replacements in peptides [1]. The 
placed between two amino acids signals the absence 
of the normal CONH linkage, and the replacing chem- 
ical moiety is specified within the bracket. 
Peptides and pseudopeptides u ed in this study 
were synthesized by solution and solid-phase methods 
[2-7]. All products were purified by a combination of 
open-column and high-performance liquid chromatog- 
raphy (HPLC) procedures, and purity was established 
by a different set of analytical HPLC parameters as well 
as by thin layer chromatography in at least two sol- 
vent systems. In some cases, products were prepared 
by two different routes (e.g., cyclization of different 
linear precursors to a common ring) to verify both 
structural and stereochemical integrity. Although the 
sulfoxides (~[CH2SO]) are configurationally stable and 
the diastereomeric pseudopeptides have in most cases 
been separable, the absolute configurations of these 
centers have not yet been established. The ~[CH2NH] 
analogues were separated and characterized as their 
acetate salts. Additional details regarding structural 
and conformational properties of these analogues are 
being collected and will be published elsewhere. 
Mass Spectrometry 
All mass spectra were acquired on a VG ZAB-4F mass 
spectrometer of BIE1-E2B2 geometry that has been pre- 
viously described [39]. This instrument is operated 
at 8 kV and is equipped with an Ion Tech saddle- 
field atom gun and a standard VG FAB source. The 
samples (approximately 1 #L of a 1 mg/mL solution) 
were dissolved in dithiothreitol/dithioerythritol matrix 
on the FAB probe tip and bombarded with 8-keV xenon 
atoms. Full-scan mass spectra were obtained by scan- 
ning MS-I with detection at the second multiplier in 
the third field-free region. Daughter ion spectra were 
acquired by collisional activation (CA) at 8 kV. The par- 
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Table 1. Backbone-modified peptides tudied by tandem mass 
spectrometry 
[CH2NH]-Modified peptide [CH2S]-Modified peptide 
Tyr-D-Ala-Gly-Phe~Leu 
Boc-Gly~Phe-OMe 
Boc-Gly~Phe-OH 
Boc-D-Lys(e-Cbz)-Gly~Phe-O Me 
Tyr-c[D-Lys-Gly-Phe~Leu] 
Tyr~-c[D-Lys-Gly-Phe-Leu] 
Tyr-D-Ala-Gly~Phe-Leu 
Tyr-D-Ala-Gly-Phe~Leu-A rg-Arg-Ile 
Frnoc-Tyr-D-Lys-Gly~Phe-Leu 
Fmoc-Tyr-D-Lys-Gly~Phe 
c [D -Lys-G ly-PheC/Leu ]
Tyr-c[D-Lys-Gly-Phe~Leu] 
Tyr-c[D-Lys-Gly~Phe-Leu] 
c[Phe-Pro~Gly-Pro-Gly] 
[CSNH]-Modified peptide [CH2SO]-Modified peptide 
Pro~Gly-Phe-Pro-Gly 
Boc-Gly~Phe-OMe 
Cbz-Leu-Gly~Leu-OMe 
c[D-Lys-Gly~Phe-Leu] 
Tyr-c[D-Lys-Gly~Phe-Leu] 
Tyr-D-Ala-Gly~Phe-Leu 
Tyr-D-Ala-Gly-Phe~Leu-Arg-Arg-Ile 
Tyr-c-[D-Lys-Gly~Phe-Leu] 
Tyr-c[D-Lys-Gly-Phe~Leu] 
ent ions were collided with helium gas (50% parent ion 
beam reduction) in the collision cell between MS-I and 
MS-II. The resulting CAD spectra were obtained by a 
linear scan of E2B 2 in a linked mode. Computerized 
mass assignments based on a linear scan function of 
B 2 were used for mass calibration. These assignments 
were verified by comparison with the mass spectra nd 
by manual mass marking [37]. The data acquisition sys- 
tem used was a VG Analytical 11-250 data system. 
Results and Discussion 
For the purposes of this discussion, we will focus on 
the MS/MS spectrum of a single modified peptide that 
is typical of its class. The fragmentation observed will 
be compared to those of the corresponding unmodi- 
fied peptide, and the impact of the backbone modifica- 
tion on the structural determination of these peptides 
will be discussed. 
Sequencing of Peptides 
Upon CA, the [M + H] + ions of unmodified linear pep- 
tides typically fragment into daughter ions by cleavage 
of the peptide backbone. The MS/MS spectrum of the 
[M + HI + ion of the peptide Tyr-D-Ala-Gly-Phe-Leu 
is shown asan  example in Figure la. The majority of 
the fragment ions observed result from peptide bond 
cleavage with charge retention on the N-terminal (i.e., 
an, bn, and Cn sequence ions) and the C-terminal (i.e., 
Xn, yn, and zn sequence ions) portions of the molecule 
with a complete N-terminal sequence being observed. 
It has been reported previously that observance of 
both N- and C-terminal ions is common in peptides 
that lack a basic amino acid residue (i.e., Lys or Arg) 
at or near a terminus [40]. 
The nomenclature for the peptide cleavages i that 
of Roepstorff and Fohlman [41] as modified by Bie- 
mann [27]. Ions due to internal fragments are desig- 
nated by the N-terminal cleavage and C-terminal cleav- 
age yielding the fragment, for example, y3b5. Note that 
this nomenclature indicates an N-terminal NH2 group 
and a C-terminal charged group such as an acylium 
ion. In all cases, the left-hand amino acid residue in 
the structures given in Table 1 is designated as the N- 
terminal amino acid, and the right-hand amino acid 
residue is designated as the C-terminal. For example, 
for the pseudopeptide C[D-Lys-Gly-Phe~Leu], Lys is 
the first amino acid residue, and for the pseudopep- 
tide Tyr-c[D-Lys-Gly-Phe~Leu], Tyr is the first amino 
acid residue. Fragments in which the pseudopeptide 
bond is broken are indicated by inclusion of a ~, as in 
y3~b4 • 
In contrast o that of linear peptides, the sequenc- 
ing of cyclic peptides is much more difficult. It has 
been reported [32, 33] that the major daughter ions 
can be interpreted in terms of protonation on a pep- 
tide nitrogen. Following protonation, a linear acylium 
ion is formed owing to opening of the peptide ring. 
Losses of amino acid residues from the C-terminus 
are then observed. For example, the spectrum of the 
[M + H] + ion of the cyclic peptide Tyr-c[D-Lys-Gly- 
Phe-Leu] (Figure lb) contains fragments Y3, which can 
be formally envisioned as arising from protonation of 
glyCine, ring opening, and loss of Tyr-Lys-Leu and b 3 
arising from protonation on ~-Lys, ring opening and 
loss of Phe-Leu. The relatively abundant fragment ion 
Xn (not usually observed in linear peptides) is a re- 
sult of the cyclic peptide [M + H] + ion undergoing c~ 
cleavage of the C--C bond adjacent to the exocydic N- 
terminal group with hydrogen migration. This obser- 
vation can be used to identify an exocyclic N-terminal 
amino acid residue. 
Methyleneamine (CH2NH) Substitution 
The CA spectrum for the modified straight-chain pep- 
tide Tyr-D-Ala-Gly-Phe~[CH2NH]Leu is shown in Fig- 
ure 2a. The [M + H] + ion of the modified peptide frag- 
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Ala-Gly-Phe-Leu and (b) the unmodified cyclic peptide Tyr-c[D-Lys-Gly-Phe-Leu]. 
ments to give ions that contain the methyleneamino 
group in high relative abundance. For example, the C- 
terminal ions Y3 and Y4, which contain the secondary 
amine, are observed in Figure 2a. In comparison, the 
unmodified parent peptide (Figure la) decomposes 
upon CA to give relatively abundant N-terminal ions 
(i.e., a4, b3, and b4) and the relatively low abundance 
ions Y3 and Y4. Another major difference that should 
be noted is that the N-terminal ion c4, a low-abundance 
ion in the decomposition f the parent peptide, is now 
present in high abundance in the CA spectrum of the 
pseudopeptide. This c4 ion is a result of cleavage of 
the NH--CH bond where the NH results from substi- 
tution of the [CH2NH] group. This same fragmenta- 
tion was observed by Lippstreu-Fisher and Gross [42] 
in the CAD spectra of polyamino alcohols. Owing to 
the presence of the [CH2NH] replacement moiety, an 
internal fragment ion at m/z 191, fragment y3¢b4 in Fig- 
ure 2a, is observed and is the result of o~. cleavage of the 
CH2--NH bond of the substituted methylene group. 
The MS/MS spectra of the [CH2NH] modi- 
fied cyclic peptides, for example, Tyr-c[B-Lys-Gly- 
Phe¢[CH2NH]Leu] (Figure 2b), do not differ as signif- 
icantly from that of the unmodified cyclic peptides as 
in the case of the linear peptides, possibly because of 
the presence of the exocyclic N-terminal group. The x4 
M'  
x, - co  
y, I 
Y4-CO I 
466 569 G66 
M" I'1) + 
H) + 
and Y4 ions (C-terminal sequence ions) arising by loss 
of the exocyclic residue are still of high relative abun- 
dance. Two new fragment ions, ysa5 and y3¢b4 (m/z 
276 and 191, respectively), which contain the modified 
[CH2NH] bond, appear. 
Thioamide (CSNH) Substitution 
Replacement of a [CONH] group in the backbone chain 
with a [CSNH] moiety seems to have little effect on the 
fragmentation f the peptide. As an example, the [M + 
H] + ion of the modified peptide Pro¢[CSNH]Gly-Phe- 
Pro-Gly fragments when activated to give a relatively 
simple daughter ion spectrum (Figure 3). Amino acid 
sequence ions are observed (i.e., b2, b3, Y2, and Y3) 
and are of relatively high abundance. Novel cleavages 
due to the presence of the thioamide moiety are of low 
relative abundance if present at all. Thus the thioamide 
bond behaves imilarly to the amide bond. 
Thiomethylene Ether (CH2S) Substitution 
Upon CA, pseudopeptides that have been modified 
by a [CHaS ] replacement group fragment to give C- 
terminal ions in high relative abundance. Th e [M + HI + 
ion of Tyr-D-Ala-Gly¢[CH2S]Phe-Leu (Figure 4a) de- 
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composes into the abundant ions of Y3 and Y4. The en- 
hancement of these fragmentations, compared to the 
CA spectrum of the parent peptide (Figure la), is sim- 
ilar to that observed in the [CH2NH]-modified peptide 
(Figure 2a). However, a major fragment ion that was 
not observed in the previous spectra is the daughter 
ion formed as a result of cleavage of the NH--CH2 
linkage (i.e., fragment z3) two bonds removed from the 
CH2S bond. This fragmentation may occur with partic- 
ipation of the sulfur to form a product ion containing a 
three-membered ring (Scheme I). This process is char- 
acteristic of the presence of the [CH2S] modification. 
The MS/MS spectra of [CH2S]-modified cyclic pep- 
tides with an exocyclic Tyr group are similar to the 
MS/MS spectra of unmodified and [CH2NH]-modified 
cyclic peptides in that the cyclic peptides tend to frag- 
ment into C-terminal ions x4 and Y4 as well as into 
N-terminal sequence ions such as those of m/z 293 
180 DETERDING ET AL. J Am Soc Mass Spectrom 1990, 1, 174-182 
R ! 
O +~=~', I 
l i /NH2~ /CH2.~ /C  H ,-,.~, 
"~"C CH 2 S 
Scheme I 
R' O 
H2C~+ I II 
HzC[ /S - -CH ~ -'1- NH2/C"~ 
(y3as) and m/z 321 (y3bs) (Figure 4b). The presence 
of the N-terminal substituent, he loss of which gives 
rise to the C-terminal x and y fragments, presumably 
promotes the observation of the C-terminal ions. In 
the absence of this substituent, hat is, in the case of 
c[Lys-Gly- Phe~Leu] as shown in Figure 4c, N-terminal 
ions are more abundant, which is similar to unmodi- 
fied cyclic peptides that undergo CA to yield predom- 
inantly N-terminal sequence ions [24, 25]. In addition, 
several unusual fragment ions arising from the pres- 
ence of the [CH2S] group are observed (i.e., m/z 275, 
[M + H-  CH2S-Lys],  and m/z 138). The ion of m[z 138 
in Figure 4c is probably due to significant rearrange- 
ments within the molecule. In Figure 4b, the cleav- 
age of the NH--CH2 bond two bonds removed from 
the S, which is characteristic of the presence of the 
[CH2S ] modification, is observed in significantly lower 
abundance than that of the comparable ion in the lin- 
ear peptide. This fragment ion, fragment f at m/z 420, 
corresponds to the loss of --(CHa)2SCHRCO (where 
R = CH2C6H5) from the protonated molecular ion. 
Thiomethylene Sulfoxide (CH2 SO) Substitution 
Linear pseudopeptides that have been modified bya  
[CH2SO] replacement group exhibit a much more com- 
plicated spectrum upon CA than, for example, those 
containing the [CH2S ] modification. However, the de- 
composition pattern is still similar to that of the previ- 
ously studied linear peptide (i.e., unmodified as well 
as [CH2NH]- and [CH2SO]-modified peptides). For ex- 
ample, the CA spectrum of the [M + H] + ion of Tyr-D- 
Ala-Gly~[CH2SO]Phe-Leu is shown in Figure 5a. The 
presence of the N-terminal ions (i.e., an and bn ions) 
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in high relative abundance is characteristic of the frag- 
mentation patterns observed in unmodif ied peptides 
(Figure la) except hat the a4 and b4 ions are not seen. 
In addition, the presence of the relatively abundant 
C-terminal sequence ions of Y3 and Y4 was  also ob- 
served in the fragmentation of both the [CH2NH]- and 
[CH2S]-modified parent peptides (Figures 2a and 4a, 
respectively). The sulfoxide group acts like a carbonyl 
group in that cleavages at the sulfoxide bond are ob- 
served (i.e., b3 and c3). 
The MS/MS spectra of [CH2SO]-modified cyclic 
peptides (Figure 5b) are also very similar to those 
of all the previously studied cyclic peptides in that 
the C-terminal ions of Y4 and x4 are the most abun- 
dant fragment ions observed. In addition, as was ob- 
served in the CA spectra of [CH2S]-modified pep- 
tides, the daughter ion resulting from cleavage of the 
NH--CH2 bond (two bonds removed from the sub- 
stituted CH2--SO linkage) is observed. This ion at 
m/z 420, fragment ion f, corresponds to the loss of 
- -(CH2)2SOCHRCO (where R = CH2C6H5) from the 
[M + H/+ ion. 
Conclusions 
Upon CA, peptides containing modifications in the 
backbone chain undergo amino acid sequence frag- 
mentations and side-chain fragmentations. Straight- 
chain peptides containing ~[CH2NH] and ~[CH2S] 
groups decompose to give predominantly C-terminal 
ions. In comparison, ~[CH2SO]-modified linear pep- 
tides fragment o give a high relative abundance of 
both N- and C-terminal ions. However, the presence 
of a ~[CSNH] group has little effect on the fragmenta- 
tion of the peptide. In addition, the backbone-modif ied 
peptides tend to give relatively more abundant C- 
terminal fragment ions than the normal unmodif ied 
peptides. This effect may be less noticeable if other 
strongly directing groups, such as Arg or Lys [33], 
or charged residues are present. Since the daughter 
ion spectra of straight-chain peptides vary with the 
presence of the amide bond replacement, useful struc- 
tural information may be obtained. The presence and 
location of the backbone modification can also be de- 
termined from the fragmentation pattern of the pseu- 
dopeptide. In contrast, the presence of a replacement 
group in the backbone of cyclic peptides can have less 
effect on the fragmentation patterns depending upon  
the presence or absence of exocyclic residues. 
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